One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. SPY
9. EVMN
10. AAPL

Go back to One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Regeneron (NASDAQ: REGN) Delayed: 804.63 -5.68 (0.7%)
Previous Close $810.31    52 Week High $592.36 
Open $803.83    52 Week Low $325.35 
Day High $808.63    P/E 211.19 
Day Low $796.73    EPS $3.81 
Volume 144,621